Immunogenicity and safety of Sanofi Pasteur's CYD dengue vaccine in healthy children and adolescents aged 9 to 16 years in Latin America

Trial Profile

Immunogenicity and safety of Sanofi Pasteur's CYD dengue vaccine in healthy children and adolescents aged 9 to 16 years in Latin America

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs CYD TDV (Primary) ; DTaP vaccine
  • Indications Dengue
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Aug 2011 Planned end date changed from 1 Jan 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 03 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top